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Survival of pancreatic cancer cells lacking KRAS
function
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Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal
adenocarcinoma (PDAC), an aggressive malignancy with few effective therapeutic options.
Despite efforts to develop KRAS-targeted drugs, the absolute dependence of PDAC cells on
KRAS remains incompletely understood. Here we model complete KRAS inhibition using
CRISPR/Cas-mediated genome editing and demonstrate that KRAS is dispensable in a subset
of human and mouse PDAC cells. Remarkably, nearly all KRAS deﬁcient cells exhibit phos-
phoinositide 3-kinase (PI3K)-dependent mitogen-activated protein kinase (MAPK) signaling
and induced sensitivity to PI3K inhibitors. Furthermore, comparison of gene expression
proﬁles of PDAC cells retaining or lacking KRAS reveal a role of KRAS in the suppression of
metastasis-related genes. Collectively, these data underscore the potential for PDAC resis-
tance to even the very best KRAS inhibitors and provide insights into mechanisms of
response and resistance to KRAS inhibition.
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Pancreatic ductal adenocarcinoma (PDAC) is the thirdleading cause of cancer death in the United States and amajor cause of morbidity and mortality worldwide1, 2.
While advances in combination chemotherapy have improved
median survival3, 4, long-term survival remains poor1, 2, high-
lighting the need for novel therapeutic approaches.
Genomic studies have identiﬁed mutations in the proto-
oncogene KRAS as a hallmark of PDAC, occurring in >90% of
cases5–8. KRAS is a small GTPase that acts as a molecular
switch to regulate proliferation, differentiation, metabolism, and
survival9. Oncogenic forms of KRAS harboring mutations in
codons 12, 13, and 61 are insensitive to GTPase activating protein
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(GAP)-induced GTP hydrolysis, leading to constitutive activa-
tion10. Studies in animal models have conﬁrmed an important
role of oncogenic KRAS in tumor initiation11, making KRAS an
attractive therapeutic target.
Unfortunately, the development of effective KRAS inhibitors
has been hindered by several features of oncogenic KRAS:
(1) its high afﬁnity for GTP, impeding the identiﬁcation of
GTP-competitive inhibitors; (2) the difﬁculty of inducing gain-of-
function hydrolytic activity with small molecules; and (3) redun-
dant pathways for membrane localization required for KRAS
activity9, 10. New approaches to directly inhibit KRAS through
covalent binding of speciﬁc mutant variants (e.g., G12C)12, 13,
interference with guanine-exchange factor (GEF) association to
prevent initial GTP loading14, 15, and destabilization of additional
membrane localization complexes16 continue to be developed.
Furthermore, the success of a recent effort spearheaded by the
National Cancer Institute of the United States to develop novel
RAS-targeted therapies17, 18 requires a better understanding of
the dependency of PDAC cells on KRAS as well as predicting
resistance mechanisms that could develop in response to KRAS
inhibition.
Given the lack of KRAS inhibitors, genetic tools have been used
to evaluate the requirement of KRAS in PDAC maintenance.
Acute KRAS knockdown by RNA interference (RNAi) decreased
cell proliferation and/or induced apoptosis in a series of human
PDAC (hPDAC) cancer cell lines19–21. Variability in apoptotic
response to KRAS knockdown led to the classiﬁcation of some
cells as “KRAS-dependent” and others as “KRAS-independent”20,
21. Based on these studies, it was unclear whether the
“KRAS-independent” phenotype was a consequence of the
incomplete inhibitory effects of RNAi such that residual KRAS
protein was sufﬁcient to sustain cell survival and proliferation.
Recent evidence for PDAC cell survival in the absence of
oncogenic KRAS expression derived from a doxycycline (DOX)-
inducible oncogenic KRAS transgenic mouse model22. In this
model, DOX treatment led to oncogenic KRAS expression in the
pancreas to initiate tumorigenesis, while DOX withdrawal halted
transgene expression and induced tumor regression. Interestingly,
a subset of PDAC tumors recurred lacking KRAS transgene
expression22. Despite these ﬁndings, the absolute dependence of
PDAC cells on endogenous KRAS, a prerequisite for the suc-
cessful clinical development of novel KRAS inhibitors, remains
unknown.
In this study, we examine the consequence of KRAS knockout
in PDAC cells using the clustered regularly interspaced short
palindromic repeats (CRISPR)/Cas system. The bacterial
CRISPR/Cas adaptive immune system, modiﬁed for genome
editing in mammalian cells, utilizes a single guide RNA (sgRNA)
to direct the Cas9 nuclease to cleave matching double-stranded
DNA (dsDNA) sequences, resulting in insertions and deletions
via error-prone non-homologous end joining repair mechan-
isms23. We conﬁrm the variable dependence of hPDAC cell lines
based on prior RNAi studies20, 21, and further isolate a subset of
hPDAC and murine PDAC (mPDAC) cells that can survive and
proliferate despite the absence of endogenous KRAS function. An
unbiased chemical screen identiﬁes sensitivity to phosphoinosi-
tide 3-kinase (PI3K) inhibition in KRAS deﬁcient cells, offering a
pharmacologically tractable method to subvert resistance to
KRAS blockade. Furthermore, we gain mechanistic insight into
how PI3K inhibition simultaneously blocks the mitogen-activated
protein kinase (MAPK) and AKT pathways to impair
cap-dependent translation and cell viability in the context of
KRAS ablation. Finally, gene expression proﬁling deﬁnes KRAS-
regulated pathways in PDAC cells and reveals KRAS-relevant
gene signatures that strongly predict survival in PDAC patients.
Results
CRISPR/Cas-mediated KRAS knockout in PDAC cells. To
evaluate the dependence of PDAC cells on endogenous KRAS, we
employed CRISPR/Cas technology23 to completely eliminate
KRAS function. We expressed Streptococcus pyogenes Cas9 and a
panel of sgRNAs targeting various KRAS exons (Supplementary
Fig. 1a and Supplementary Table 1) in KRAS mutant hPDAC and
mPDAC cell lines to identify sgRNAs that effectively induced
KRAS protein loss (Supplementary Fig. 1b). Given the lack of
unique protospacer adhesion motifs (PAM) encompassing
mutant codon 12, our sgRNAs did not discriminate between
wild-type and mutant forms of KRAS, modeling non-selective
KRAS inhibition, which comprises the vast majority of approa-
ches currently being evaluated to target KRAS18. The con-
sequence of short-term CRISPR/Cas-mediated KRAS knockout
mimicked the effect of short hairpin RNA (shRNA)-mediated
KRAS knockdown on cell viability (Supplementary Fig. 1c, d).
Consistent with published results20, previously deﬁned “KRAS-
independent” cells (8988T, PANC-1) were largely insensitive to
sgRNA transduction, while “KRAS-dependent” cells (8902)
exhibited signiﬁcantly decreased viability (Supplementary
Fig. 1e).
We further generated single cell subclones to evaluate
whether PDAC cells could survive in the complete absence of
KRAS expression. We isolated KRAS deﬁcient subclones
from 8988T hPDAC and A13 mPDAC cells (Fig. 1a and
Supplementary Fig. 2c) and conﬁrmed decreased total RAS
activity (RAS-GTP) (Fig. 1b). Sanger sequencing revealed indels
in the KRAS locus leading to premature stop codons or in-frame
indels of important functional domains24 (Supplementary
Fig. 2a, b), likely perturbing protein folding and stability.
PDAC cells that survived KRAS loss exhibited perturbations
of several growth characteristics. KRAS deﬁcient cells
displayed altered morphology (Fig. 1c and Supplementary Fig. 2d)
comparable to that observed with KRAS knockdown (Supple-
mentary Fig. 1d), signiﬁcantly diminished anchorage-
independent colony formation (Fig. 1d and Supplementary
Fig. 2e), and slower proliferation in 2D and 3D culture (Fig. 1e
and Supplementary Fig. 2f). Interestingly, KRAS deﬁcient
Fig. 1 KRAS is dispensable for in vitro and in vivo proliferation of PDAC cells. aWestern blot conﬁrmed loss of KRAS protein in knockout clones (A13-K1,K2,
8988T-H9,H36) compared to intact clones (A13-E1,E2, 8988T E3, E6). HSP90 is loading control. b RAS-GTP levels were decreased in knockout (8988T-
H9 and A13-K1,K2) compared to intact (8988T E3 and A13-E1,E2) clones. GTPγS (non-hydrolysable)-treated positive control (GTP PD) and GDP-treated
negative control (GDP PD) for 8988T E3 are shown. PD pull-down. Inp input before pull-down. c KRAS deﬁcient clones exhibited altered cell morphology,
characterized by increased cell size, cytoplasmic translucency, and smooth edges. Scale bar is 100 µm. d KRAS deﬁcient clones showed diminished
anchorage-independent growth in soft agar. Scale bar is 500 µm. e Growth curves for A13 and 8988T KRAS intact and deﬁcient (KO) clones. Average cell
viability (normalized to day 0)± s.e.m. is plotted for A13 (n= 2 clones) and 8988T (n= 4 clones). f A13, 8988T, and PANC-1 clones exhibited comparable
efﬁciency generating tumors following subcutaneous transplant in nude mice regardless of KRAS status. Shown are cumulative data from two KRAS intact
and two deﬁcient clones for A13 and 8988T and one intact and one deﬁcient clone for PANC-1. g A13 KRAS deﬁcient tumors grew at a slower rate than
intact tumors. Average tumor volume fold increase (normalized to day 0 when tumors were ~0.5 cm in diameter)± s.e.m. is plotted (n= 8 tumors per
group)
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cells retained the ability to form subcutaneous tumors in
immunocompromised mice (Fig. 1f), though tumors grew more
slowly (Fig. 1g).
To ensure that the observed phenotypes were due to on-target
KRAS mutagenesis, we sequenced the closest exonic sgRNA
mismatches and found no off-target mutations in these loci
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Fig. 2 KRAS is dispensable in a subset of PDAC cell lines. a Western blot conﬁrmed loss of KRAS protein in knockout clones derived from PANC-1 (P2
complete, P3 partial), KP-4 (P1, P2, P3, P4), and MM1402 (H1, H2) cell lines compared to intact clones (PANC-1-E1,E2; KP-4-E1,E2; MM1402-E1,E2,E3). HSP90
is loading control. b KRAS deﬁcient clones (purple) exhibited altered cell morphology compared to intact cells (gray). Speciﬁc differences include increased cell
size, cytoplasmic translucency, and smooth edges. Scale bar is 100 µm. c KRAS deﬁcient clones showed diminished proliferation in vitro. Average cell viability
(normalized to day 0)± s.e.m. for each clone is plotted. PANC-1 knockout clone (P2) and partial knockout clone (P3) exhibited a dose-dependent effect of
KRAS expression on proliferation compared to intact clones (E1, E2). d PANC-1, KP-4, and MM1402 KRAS deﬁcient clones showed diminished soft agar colony
formation. PANC-1 cells displayed a dose-dependent effect of KRAS expression on anchorage-independent growth. Scale bar is 500 µm
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(Supplementary Fig. 3a, b). Furthermore, NRAS and HRAS
expression were unaltered, consistent with KRAS speciﬁcity of the
sgRNAs (Supplementary Fig. 3c). Mutation analysis of RNA-
sequencing (RNA-Seq) from 8988T (Supplementary Data 1) and
A13 (Supplementary Data 2) subclones did not reveal recurrent
protein-coding single nucleotide polymorphisms in expressed
genes distinguishing all intact and deﬁcient clones. Finally, we re-
expressed oncogenic KRAS in deﬁcient clones (Supplementary
Fig. 3d), and observed a reversal in cell morphology (Supple-
mentary Fig. 3e), in vitro proliferation (Supplementary Fig. 3f),
and soft agar colony formation (Supplementary Fig. 3g).
Together, these data demonstrate that KRAS knockout
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Fig. 3 KRAS deﬁcient cells are dependent on PI3K. a Heat map of area under the curve (AUC) for KRAS intact and deﬁcient (KO) clones (columns) treated
with various compounds. Row normalized data are presented with red designating high AUC (less sensitive) and blue denoting low AUC (more sensitive).
Shown are hit compounds (see “Methods” section) exhibiting greater sensitivity in KRAS deﬁcient cells listed in order of ΔAUC from highest to lowest.
PI3K and mTOR inhibitors are noted. See Supplementary Data 4 for full data set. b Dose-response curves of 8988T KRAS intact (gray) and deﬁcient
(purple) cells to the pan-PI3K inhibitors GDC-0941 and BAY80-6946. Each replicate (n= 3 for each dose) and curve ﬁt are shown. c Increased apoptosis
(change in percentage Annexin V-positive cells vs. DMSO) in KRAS deﬁcient (KO) cells 48 h after 2 μM GDC-0941 treatment. Average± s.e.m. is plotted
(n= 2 clones per group). *p< 0.05, two-tailed Student’s t test. d Dose-response curves of A13 cells to pan-PI3K inhibitors. Each replicate (n= 3 for each
dose) and curve ﬁt are shown. e GDC-0941 signiﬁcantly decreased the growth rate of KRAS deﬁcient (KO) but not intact A13 transplanted tumors in nude
mice. Average tumor volume fold increase (normalized to start of treatment at day 0)± s.e.m. (n= 8 tumors per group) is plotted. *p< 0.05, **p< 0.01,
two-tailed Student’s t test for measurements at each time point comparing GDC-0941 to vehicle
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signiﬁcantly impacts proliferation in vitro and tumorigenic
growth in vivo, conﬁrming the importance of KRAS in PDAC
cell maintenance.
KRAS is dispensable in a subset of PDAC cells. We next eval-
uated the frequency of KRAS independence in a larger panel of
KRAS mutant hPDAC and mPDAC cell lines derived from
multiple models of KRAS-driven murine PDAC (Supplementary
Table 2). We successfully isolated KRAS deﬁcient clones from the
hPDAC cell lines PANC-1 and KP-4 and the mPDAC cell
line MM1402 (Fig. 2a). These additional KRAS deﬁcient cells
exhibited cellular features comparable to those observed in 8988T
and A13 knockout cells, including alterations in cell morphology
(Fig. 2b), decreased proliferation in vitro (Fig. 2c), and dimin-
ished anchorage-independent growth (Fig. 2d). In contrast, we
were unable to derive KRAS deﬁcient clones from hPDAC cell
lines 8902, YAPC, and PSN-1 and mPDAC cell lines D8, E, F, and
MM1404, as these cell lines either generated clones that retained
KRAS protein (e.g., 8902 and PSN-1, Supplementary Fig. 4a) or
did not form recoverable clones at all (e.g., YAPC).
Interestingly, cell lines with lower KRAS protein levels
exhibited greater tolerance for KRAS knockout (Supplementary
Fig. 4b). Recent work has suggested that increased target copy
number can permit CRISPR/Cas-mediated lethality in a gene-
independent fashion25. Indeed, we observed that increased KRAS
copy number correlated with decreased capacity to generate
knockout clones, especially in hPDAC cell lines (Supplementary
Fig. 4c). Nonetheless, KRAS deﬁcient cells could be isolated from
some cell lines (e.g., KP-4 and PANC-1) despite having similarly
elevated KRAS copy number to cell lines that did not generate
knockout clones (e.g., 8902). Together, these data are consistent
with prior work20 and suggest that KRAS protein levels may be a
biomarker of sensitivity to KRAS inhibition in PDAC cells.
Overall, half (3/6) of established hPDAC and one-third (2/6)
of primary and established mPDAC cell lines had the capacity
to generate KRAS deﬁcient clones (Supplementary Table 3),
suggesting absolute KRAS independence is not an isolated
phenomenon. Moreover, we cannot exclude the possibility that
screening additional clones could identify KRAS deﬁcient cells
even in parental cell lines from which we have been unable to
recover knockout clones to date. Nonetheless, endogenous KRAS
is dispensable in a large fraction of PDAC cells, underscoring the
potential for resistance to even the very best KRAS inhibitors.
KRAS knockout cells exhibit PI3K dependence. We next sought
to elucidate the mechanisms that permit the proliferation and
survival of PDAC cells in the absence of KRAS. While previous
work reported that marked overexpression of YAP1 could
support the growth of a subset of PDAC tumors following loss of
KRAS expression22, 26, we did not observe similar elevations in
YAP1 protein levels in KRAS deﬁcient compared to intact cells
(Supplementary Fig. 5a). Moreover, KRAS deﬁcient cells did
not exhibit increased sensitivity to verteporﬁn, a YAP–TEAD
interaction inhibitor27, or to YAP1 knockdown/knockout
compared to intact cells (Supplementary Fig. 5b–f). Therefore, we
employed high-throughput drug screening to identify unique
dependencies in KRAS deﬁcient cells. We screened 8988T KRAS
intact and deﬁcient clones against a compound library comprised
of kinase inhibitors, epigenetic modiﬁers, and chemotherapeutic
agents, many of which are being tested in clinical trials or are
FDA approved (Supplementary Data 3). While no compound
selectively impaired the viability of KRAS intact cells, deﬁcient
c
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cells exhibited increased sensitivity to pan-PI3K and mTOR
inhibitors (Fig. 3a and Supplementary Data 4). As dose-response
curves and direct observation suggested a cytotoxic effect of
pan-PI3K inhibitors rather than the cytostatic effect of mTOR
inhibition (Supplementary Fig. 6), we chose to further char-
acterize the consequence of PI3K inhibition on KRAS deﬁcient
cells.
We conﬁrmed enhanced sensitivity to the pan-PI3K inhibitors
GDC-0941 and BAY80-6946 in additional 8988T KRAS deﬁcient
clones (Fig. 3b and Supplementary Fig. 7a) and that GDC-0941
increased apoptosis in deﬁcient cells (Fig. 3c). In addition, we
found that A13 KRAS deﬁcient clones were more sensitive to
PI3K inhibition than their intact counterparts both in vitro and
in vivo (Fig. 3d, e). Finally, KP-4 and MM1402, but not PANC-1,
knockout clones demonstrated increased sensitivity to GDC-0941
(Supplementary Fig. 7a). Treatment of 8988T and A13 clones
with combinations of PI3K class I isoform-speciﬁc inhibitors
revealed a synergistic effect of p110α inhibition with p110β- or
p110δ-speciﬁc inhibitors (Supplementary Fig. 7b, c), suggesting
the need for pan-class I PI3K inhibition for full effect.
Biochemically, we observed stable MAPK phosphorylation but
signiﬁcantly increased PI3K/AKT pathway activation in 8988T
and A13 deﬁcient cells (Fig. 4a and Supplementary Fig. 7d, e).
Interestingly, MM1402 and PANC-1, but not KP-4, knockout
cells also showed increased pAKT levels at steady state
(Supplementary Fig. 7f). These data suggest that PI3K/AKT
hyperactivation and PI3K inhibitor sensitivity are features of
most PDAC cells following KRAS knockout.
We next explored the mechanisms underlying PI3K/AKT
activation in 8988T and A13 KRAS deﬁcient cells. As activating
PI3K pathway mutations (Supplementary Data 1 and 2) and
changes in the protein levels of the phosphoinositide phospha-
tases PTEN and INPP4B (Supplementary Fig. 8a) were not
observed in deﬁcient cells, we hypothesized that feedback
stimulation of PI3K by upregulated receptor tyrosine kinases
(RTKs)28–30 could be occurring. While we observed PDGFRβ and
FGFR2 upregulation in KRAS deﬁcient cells (Supplementary
Fig. 8b), inhibition of PDGFR and FGFR alone or in combination
did not show a greater effect on the proliferation of deﬁcient cells
(Supplementary Fig. 8c). Similarly, RTK array proﬁling of A13
intact and deﬁcient clones did not reveal signiﬁcant differences in
phosphorylation across a broader array of RTKs (Supplementary
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Fig. 8d). In contrast, stimulation with any of the RTK ligands
EGF, PDGF-BB, or FGF1 decreased sensitivity of deﬁcient cells to
PI3K inhibition (Supplementary Fig. 8e, f). Together, these data
suggest that individual RTKs may be sufﬁcient but not necessary
to support PI3K activation in KRAS deﬁcient cells, indicating
compensatory mechanisms. Nonetheless, PI3K represents a
convergent node in PDAC cells lacking KRAS function.
Simultaneous MAPK and AKT blockade by PI3K inhibition.
To dissect the mechanism underlying PI3K inhibitor sensitivity in
KRAS deﬁcient cells, we evaluated the effect of the pan-AKT
inhibitor MK2206 on cell viability in vitro. Surprisingly, AKT
inhibition did not recapitulate the differential sensitivity observed
with PI3K inhibition in 8988T and A13 cells (Fig. 4b). In contrast,
overexpression of constitutively active myristoylated (myr) forms
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of AKT1 or AKT2 (but not the kinase-dead mutant AKT1
(K179M)) prevented GDC-0941-induced AKT pathway inhibi-
tion and markedly decreased PI3K inhibitor sensitivity (Fig. 4c, d
and Supplementary Fig. 9a–d). Overall, PI3K inhibitor-mediated
AKT blockade is necessary but insufﬁcient for its effect on cell
viability.
Recent work indicated that PI3K inhibitors inactivate the
MAPK pathway in cells harboring PI3K pathway mutations to
induce apoptosis31, 32. Indeed, while GDC-0941 sustainably
suppressed pAKT in both KRAS intact and deﬁcient cells, a
transient acute decrease in pERK1/2 levels lasting minutes to
hours only occurred in deﬁcient cells (Fig. 5a, b and Supplemen-
tary Fig. 10a, b). Surprisingly, the effect of GDC-0941 appeared to
be due to inhibition of wild-type RAS activity upstream of the
MAPK pathway, as RAS-GTP, pCRAF, and pMEK1/2 levels were
diminished in KRAS deﬁcient cells (Fig. 5c, d). Consistent with
this observation, GDC-0941 also induced a decline in pERK1/2
levels in KRAS wild-type hPDAC BxPC3 and 293 human
embryonic kidney cells (Supplementary Fig. 10c).
Several lines of evidence support the hypothesis that simulta-
neous MAPK and AKT inhibition by GDC-0941 underlie its
therapeutic effect in the absence of oncogenic KRAS. First, in
PANC-1 KRAS deﬁcient cells, which do not exhibit enhanced
PI3K inhibitor sensitivity, GDC-0941 effectively suppressed
phosphorylation of AKT without inducing a decrease in
pERK1/2 levels (Supplementary Fig. 10c). Second, the MEK
inhibitor AZD6244 synergized with MK2206 in both KRAS intact
and deﬁcient 8988T and A13 cells (Supplementary Fig. 10d).
However, while AZD6244 enhanced the effect of GDC-0941 on
KRAS intact cells, such synergy was absent in deﬁcient cells
(Supplementary Fig. 10e), likely due to the MAPK inhibitory
effect already provided by GDC-0941. Finally, overexpression of
constitutively active MEK (MEK-DD) or sgRNA-resistant onco-
genic KRAS (but not wild-type KRAS) prevented pERK1/2 decline
and reduced PI3K inhibitor sensitivity in deﬁcient cells (Fig. 5e, f
and Supplementary Fig. 10f, g).
Prior research has suggested that the MAPK and AKT
pathways may converge on the 4EBP1-EIF4E axis to regulate
cap-dependent translation in cancer cells33, 34. Interestingly,
oncogenic gene signatures associated with the cap-dependent
translation mediators MYC and EIF4E35, 36 were enriched in gene
expression analysis of 8988T KRAS intact cells (MSigDB/GSEA,
Supplementary Data 11), suggesting that KRAS may also regulate
this process in this cell line. While we did not observe a difference
in MYC protein levels (Supplementary Fig. 8a), baseline phospho-
4EBP1 levels were reduced in 8988T KRAS deﬁcient cells
(Supplementary Fig. 7d), permitting enhanced 4EBP1 sequestra-
tion of EIF4E to restrain cap-dependent translation. Furthermore,
KRAS deﬁcient cells exhibited greater sensitivity to inhibitors of
mTOR (Supplementary Fig. 6b), an important upstream regulator
of translational control mediated through 4EBP1 phosphoryla-
tion. Therefore, we hypothesized that GDC-0941 treatment might
further decrease 4EBP1 phosphorylation in these KRAS deﬁcient
cells, pushing them beyond a threshold to functionally impair
cap-dependent translation. To test this, we transduced 8988T
KRAS intact and deﬁcient cells with an mCherry-IRES-GFP
translation reporter (Fig. 6a). KRAS deﬁcient cells exhibited a
more marked decrease in cap-dependent translation when treated
with GDC-0941 or the mTORC1/2 inhibitor AZD8055 than
intact cells (Fig. 6b). Moreover, the effects of GDC-0941 on cell
viability, 4EBP1 phosphorylation, and cap-dependent translation
were rescued by overexpression of myr-AKT1 but not myr-AKT1
K179M (Figs. 4c, d and 6c and Supplementary Fig. 9c, d). Taken
together, cap-dependent translation may be a node of MAPK and
AKT convergence, which underlies the sensitivity to PI3K
inhibition in KRAS deﬁcient cells.
Combined KRAS and PI3K inhibition as a therapeutic
approach. In order to recapitulate the therapeutic effect of
combined KRAS and PI3K inhibition in established PDAC
tumors in vivo, we engineered A13 cells to stably express Cas9
and a DOX-inducible KRAS-targeting sgRNA (mmKras.366) and
generated clones that efﬁciently ablated KRAS protein expression
following DOX treatment in vitro (Fig. 7a). To account for clonal
and animal differences, we subcutaneously transplanted two
clones, one on each ﬂank, in immunocompromised mice. Nota-
bly, there was minimal variation in tumor growth rate between
the two clones. Following tumor establishment, administration of
DOX feed led to mmKras.366 expression in established tumors
and acute suppression of tumor growth (Fig. 7b). Importantly,
KRAS inhibition alone was insufﬁcient to maintain tumor
growth suppression, possibly due to selection of escapers
harboring non-frameshift mutations and/or cells that bypassed
the requirement of KRAS by PI3K/AKT activation. Supporting
the latter hypothesis, subsequent treatment with GDC-0941 more
markedly suppressed the growth of KRAS knockout tumors
(Fig. 7b).
Western blotting of tumors conﬁrmed decreased KRAS protein
levels following DOX administration (Supplementary Fig. 11a, b)
and on-target inhibition of AKT phosphorylation with
GDC-0941 treatment (Supplementary Fig. 11a, c). As with
in vitro knockout, we saw increased phosphorylation of AKT
with in vivo KRAS knockout (Supplementary Fig. 11a, c).
Interestingly, we observed an increase in KRAS protein levels in
DOX-treated mice also treated with GDC-0941 compared to
vehicle (Supplementary Fig. 11b), suggesting selective depletion of
KRAS knockout cells and outgrowth of technical escapers that did
not efﬁciently induce loss-of-function mutations in KRAS. To
evaluate for this directly, we performed massively parallel
sequencing to analyze allelic fractions of the KRAS locus from
these tumors (Supplementary Fig. 11d, e) with the hypothesis
that there would be an increase in the proportion of
non-frameshift (NFS) mutant reads (protein retained) compared
to frameshift (FS) reads (protein loss) in tumors subject
to combined DOX and GDC-0941 treatment. In pairwise
comparisons of DOX +GDC-0941 tumors (n= 6) with each of
the DOX tumors (n= 6), the NFS mutant read fraction was found
to be signiﬁcantly enriched in the DOX +GDC samples in 72%
(26/36) of all comparisons (χ2-test of proportions, p< 0.05).
Collectively, these data demonstrate that PI3K inhibition
Fig. 6 PI3K inhibition enhances cap-dependent translation inhibition in KRAS deﬁcient cells. a Schematic of cap-dependent translation reporter construct.
5′-LTR 5′ long terminal repeat of MSCV virus with promoter activity. In transduced cells, mCherry expression correlates with cap-dependent translation
and GFP expression correlates with cap-independent translation initiated via an internal ribosomal entry site (IRES). b FACS plots of GFP and mCherry
ﬂuorescence in KRAS intact and deﬁcient (KO) cells. KRAS deﬁcient cells exhibited a greater decrease in mCherry (relative to GFP) expression when
treated for 24 h with GDC-0941 (2 μM) or the mTORC1/2 inhibitor AZD8055 (100 nM) than intact cells. Triangle gates were drawn along the midline
diagonal of the FACS plots of DMSO-treated cells and maintained in plots of drug treatment. Numbers denote percentages of cells within gate and is
inversely related to cap-dependent translation of reporter. c FACS plots of GFP and mCherry ﬂuorescence in KRAS deﬁcient cells transduced with myr-AKT1
or myr-AKT1 (K179M). Wild-type AKT1 expression decreased the effect of GDC-0941 on cap-dependent translation compared to its kinase-dead variant
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synergizes with acute KRAS inhibition in vivo, highlighting that
this combination may be a viable therapeutic strategy in
established PDAC tumors.
To further evaluate combined KRAS and PI3K inhibition as a
therapeutic strategy in a clinically relevant system, we utilized
CRISPR/Cas-mediated genome editing to generate KRAS deﬁ-
cient clones from low-passage primary patient-derived KRAS
mutant hPDAC cell lines. Importantly, we were able to isolate
deﬁcient clones from both cell lines analyzed (Fig. 7c, d and
Supplementary Tables 2 and 3). Similar to established hPDAC
cell lines, KRAS deﬁcient clones derived from primary hPDAC
cell lines demonstrated enhanced sensitivity to PI3K inhibition
(Fig. 7e) and combined MAPK and AKT blockade following
pharmacological PI3K inhibition (Fig. 7f). Together, these data
support the synergy of KRAS and PI3K inhibition in a variety of
in vitro and in vivo PDAC models.
Identiﬁcation of KRAS-regulated pathways in PDAC cells.
In addition to elucidating mechanisms of resistance to KRAS
inhibition, we uncovered key biological processes regulated by
KRAS in PDAC cells by comparing the gene expression proﬁles
of KRAS intact and deﬁcient cells. Speciﬁcally, we performed
RNA-Seq on multiple 8988T and A13 clones. Unsupervised
hierarchical clustering cleanly segregated intact from knockout
clones (Fig. 8a), and pairwise differential expression analysis
identiﬁed a large number of genes with signiﬁcantly altered
expression (Supplementary Data 5 and 6). We performed
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independent component analysis (ICA), a blind source separation
approach (see “Methods” section), to generate high-resolution
gene signatures associated with KRAS knockout (Supplementary
Fig. 12a, b and Supplementary Data 7 and 8). To gain insight into
the knockout signature, we performed gene set enrichment ana-
lysis (GSEA)37, 38 across gene expression data sets in MSigDB38.
As internal validation of our analysis, GSEA revealed anti-
correlation of the knockout signatures with genes upregulated by
expression of oncogenic KRAS in primary epithelial cells (Sup-
plementary Data 9–12). We further compared our gene signatures
to data sets generated using the DOX-inducible KRAS transgene
mouse model to modulate KRAS levels22, 39, 40. Given the high
degree of heterogeneity observed between tumors and conditions
in these data sets, we used ICA (Supplementary Data 13) to
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identify KRAS-ON and KRAS-OFF signatures
associated with acute (24-h) KRAS withdrawal8 (Supplementary
Fig. 12c), surviving cells following longer-term KRAS with-
drawal13 (Supplementary Fig. 12d), and KRAS-independent
relapsed tumors in mice9 (Supplementary Fig. 13a). The KRAS-
OFF signatures from these data sets were strongly enriched in our
knockout signatures (Supplementary Fig. 13b), supporting the
robustness of our KRAS knockout signatures across species and
model systems.
We next examined GSEA results to identify key pathways
regulated by KRAS in PDAC cells (Supplementary Data 14–17).
A13 knockout cells showed statistically signiﬁcant enrichment of
a limited number of curated gene sets in pathways previously
associated with KRAS, including EMT, integrin, and receptor
tyrosine-kinase (RTK) signaling, and redox metabolism20, 41, 42
(Fig. 8b). In contrast, 8988T cells exhibited alterations in a large
number of biologic processes (Fig. 8c). Consistent with cellular
phenotypes, 8988T knockout cells showed decreased expression
of genes related to cell cycle progression, nucleotide metabolism,
and oxidative phosphorylation (Fig. 8c). Importantly, we
uncovered novel gene expression changes associated with KRAS
function, including alterations in the expression of genes
associated with ribosomal biogenesis, protein translation, and
interferon response genes.
KRAS-relevant signatures predict survival in PDAC patients.
Recent data from mouse models demonstrated an inverse rela-
tionship between proliferation and metastatic capacity in
PDAC43. Interestingly, we observed a similar inverse relationship
in the expression of genes associated with cell proliferation (cell
cycle progression, nucleotide metabolism, and protein transla-
tion) and those associated with the metastatic process (EMT,
invasion, and integrin pathways) based on KRAS status (Fig. 8b,
c). Moreover, our knockout signatures were strongly enriched in
gene expression signatures derived from circulating tumor cells
(CTCs) (compared to primary tumors) in a Kras;p53 mutant
PDAC model44 (Fig. 9a, b). Therefore, we hypothesized that the
KRAS knockout signatures may predict worse patient survival.
We analyzed data from The Cancer Genome Atlas (TCGA)
and ranked early stage (mostly resected) primary human PDAC
tumors based on gene expression correlation to the knockout
signatures (Supplementary Data 18). As predicted, we observed
that tumors highly correlated with either the 8988T or A13
knockout signatures were associated with poor patient survival
(Supplementary Fig. 14a). The tumors most correlated with the
knockout signatures expressed genes associated with EMT,
invasion, focal adhesion/integrin signaling, and metastasis
(Supplementary Fig. 14b, c). Despite their poor prognosis, these
tumors showed decreased expression of ribosomal biogenesis,
protein translation, oxidative phosphorylation, and cell cycle
progression genes (Supplementary Fig. 14b, d). In these survival
analyses, we noticed that tumors most correlated with the 8988T
or A13 knockout signatures had non-signiﬁcant overlap (p= 0.44,
hypergeometric test). In contrast, tumors least correlated with the
knockout signatures were largely the same regardless of the cell
line from which the signature was derived (p= 1.04 × 10−7,
hypergeometric test). This suggested that loss of oncogenic KRAS
function leads to the de-repression of genes that promote a more
aggressive phenotype. Consistent with this hypothesis, the murine
CTC signature exhibited enrichment of gene sets downregulated
by oncogenic KRAS expression in various cell types (Supplemen-
tary Fig. 9c).
We next integrated our hPDAC and mPDAC gene expression
proﬁles to deﬁne a core set of KRAS-regulated genes with greater
prognostic value. We jointly analyzed the 8988T and
A13 signatures to generate a 32-gene knockout signature (see
“Methods” section, Fig. 8d). While the downregulated genes in
this set related to MAPK signaling (DUSP4, DUSP9, SPRY4,
ETV1, ETV4, ETV5), the upregulated genes supported pathways
involved in the metastatic cascade, including EMT (TGFB2,
PBX1, FGFBP1), cell adhesion (FLRT3, ICAM1), and extracellular
matrix breakdown (MMP19,MMP28). Strikingly, ranking tumors
by expression of just the 16 upregulated genes was sufﬁcient to
improve prediction of PDAC patient survival in the TCGA cohort
in multivariable analyses (Fig. 9e, Supplementary Fig. 14e, and
Supplementary Data 18). We conﬁrmed the prognostic capability
of this 16-gene signature for survival in a separate PDAC patient
cohort from the International Cancer Genome Consortium
(ICGC)45 (Fig. 8f and Supplementary Table 4). Collectively,
these data offer an independent prognostic gene signature to
predict survival in early stage patients with PDAC and implicate
loss of KRAS-related transcriptional suppression as a potential
mechanism toward PDAC metastasis.
Finally, we examined whether our knockout signature was
associated with a particular subtype of pancreatic cancer, as
deﬁned by recent gene expression proﬁling studies21, 45, 46.
Univariate and multivariable Cox regression analyses suggested
that our combined knockout signature and subtype-speciﬁc
signatures, including the quasi-mesenchymal21, basal46, and
squamous45 subtypes deﬁned from three independent human
PDAC cohorts, were associated with worse survival within the
TCGA PDAC cohort (Fig. 10a). Consistent with these results,
Kaplan–Meier survival analysis using our knockout signature
mirrored those seen with the subtype-speciﬁc signatures
(Fig. 10b). Interestingly, we observed statistically signiﬁcant
overlap between the TCGA tumors most correlated (or least
correlated) with our knockout signature and tumors most
correlated (or least correlated) with these subtype-speciﬁc
signatures (Fig. 10c). Based on these ﬁndings, we hypothesize
that the quasi-mesenchymal, basal, and squamous subtypes all
deﬁne a common set of tumors with distinct biology, impact on
survival, and decreased KRAS function.
Fig. 8 Multiple dysregulated cellular processes in KRAS deﬁcient cells. a Unsupervised hierarchical clustering dendrograms of 8988T and A13 clones
indicated clean segregation between KRAS intact and deﬁcient (KO) cells within each cell line. b Network representation of overlapping enriched GSEA/
MSigDB gene sets in the A13 knockout signature (p< 0.05, FDR< 0.25). Each circle represents a gene set with circle size corresponding to gene set size
and intensity corresponding to enrichment signiﬁcance. Red is upregulated and blue is downregulated. Each line corresponds to minimum 50% mutual
overlap with line thickness corresponding to degree of overlap. Cellular processes associated with related gene sets are listed. c Network representation of
overlapping enriched GSEA/MSigDB gene sets in the 8988T knockout signature (p< 0.005, FDR< 0.1). d Heat map of a 32-gene combined knockout
signature generated through ICA analysis of A13 and 8988T gene expression data sets. Gene names are listed in rows. Row normalized gene expression
values are shown where red designates relative upregulation and blue designates relative downregulation. e Kaplan–Meier plots of survival of human
patients from the TCGA PDAC cohort whose tumors most correlated (top quintile) and least correlated (bottom quintile) with the combined knockout
signature in d (UP genes only). Log-rank (Mantel–Cox) p value is shown. f Kaplan–Meier plots of survival of human patients from the ICGC cohort whose
tumors most correlated (top quintile) and least correlated (remaining tumors) with the combined knockout signature in d (UP genes only). Log-rank
(Mantel–Cox) p value is shown
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Fig. 9 KRAS knockout signatures correlate with CTC gene expression. a Unsupervised hierarchical clustering and ICA analysis of single cell RNA-Seq data
from Ting et al.44 using circulating tumor cells (CTCs) and primary tumor cells from a Kras;p53 mutant mouse model. ICA analysis identiﬁed a signature
(component 1 (IC1) in Hinton diagram) that distinguished CTCs from primary tumors (p< 0.01, Mann–Whitney U-test). b GSEA plots of 8988T and A13
knockout signatures (top/bottom 2% genes) enriched in ICA-derived CTC signature shown above. Normalized enrichment scores (NES) and p values are
listed for each gene set. c Signiﬁcantly enriched MSigDB gene sets in CTCs include genes downregulated (DN) following KRAS expression in the KrasLA2
lung cancer mouse model (Sweet), mouse ﬁbroblasts (Chiaradonna), and in primary human lung and breast epithelial cells (KRAS.600). NES, p values, and
FDR are listed for each gene set
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Discussion
Here we investigated the consequence of complete endogenous
KRAS ablation in PDAC cells. By inducing loss-of-function
mutations in KRAS, we modeled the cellular effects of complete
inhibition to predict resistance mechanisms to KRAS inhibition
and to uncover KRAS-regulated pathways in PDAC. Given the
signiﬁcant adverse effects of KRAS knockout on in vitro
proliferation and in vivo tumorigenic growth even in knockout-
tolerant cells, our study adds to prior work supporting the merit
of KRAS-directed therapies for PDAC10, 18. Furthermore, the
dose-response relationship between KRAS levels and cellular
phenotypes observed (e.g., PANC-1 clones in Fig. 2) highlights
a Univariate analysis
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Fig. 10 KRAS knockout signature overlaps with subtype-speciﬁc signatures of PDAC. a Univariate and multivariable Cox proportional hazards models on
overall survival in the entire TCGA PDAC cohort, including clinical covariates and gene expression signatures, revealed that the combined KRAS knockout
signature was independently associated with worse survival. Hazard ratios (HR) and p values (Cox regression) are reported. A comparison between a
model with and without an interaction term (likelihood ratio test) was used to determine independence (p> 0.05) between signiﬁcant covariates in
multivariable analysis and the combined KRAS knockout signature. b Kaplan–Meier plots of survival in human PDAC patients from the TCGA cohort based
on tumors most correlated (top quintile) and least correlated (bottom quintile) with the quasi-mesenchymal (QM) subtype from Collisson et al.21, basal
subtype signature from Mofﬁtt et al.46, and the squamous subtype signature from Bailey et al.45 (n= 33 most correlated and n= 33 least correlated
tumors). Log-rank (Mantel–Cox) p values are shown. c Tables show percentage of tumor/patient overlap of top (most correlated) and bottom (least
correlated) quintiles of tumors (out of n= 33 per group) in each signature. Green shading corresponds to degree of overlap (white= 0%, dark green=
100%). p values for signiﬁcance of overlap (between n= 33 groups) within the TCGA PDAC cohort (out of 166 total tumors) are also shown
(hypergeometric test). Red shading corresponds to signiﬁcance of overlap (white= 0.05, dark red=minimum p value)
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the therapeutic beneﬁt of developing the most potent inhibitor
possible. With the signiﬁcant public and private investment
toward the generation of novel KRAS-targeted drugs17, 18,
elucidation of potential resistance mechanisms concurrent with
the development of these inhibitors will facilitate their effective-
ness in the clinic.
Recent studies have implicated YAP1 overexpression as a
means to escape KRAS inhibition in a subset of tumors and cell
lines22, 26. Our KRAS knockout cells revealed an alternative
bypass mechanism supported by canonical (i.e., AKT pathway)
and non-canonical (i.e., MAPK pathway) PI3K signaling.
Given the variety of resistance mechanisms that arise in response
to tyrosine-kinase inhibition in RTK-mutated cancers, it is
unsurprising that multiple pathways could maintain PDAC cell
survival following KRAS inhibition in various contexts.
Importantly, we observed PI3K dependence in KRAS deﬁcient
clones derived from 6/7 (86%) parental cell lines, suggesting that
PI3K represents a convergent target regardless of tumor cell line
or species of origin.
While PI3K signaling can contribute to PDAC development in
mouse models, its role in PDAC maintenance has been less clear.
Expression of oncogenic PIK3CA in the developing pancreas
phenocopies pancreatic cancer initiation and progression
observed in KRAS mutant mice47, 48. In contrast, PI3K inhibition
alone has only marginal beneﬁt in preclinical mouse PDAC
models, whereas combination therapies with MEK inhibition
demonstrate signiﬁcantly greater anti-tumor effects49–51. In
accordance, combined MAPK and AKT blockade exhibited by
single-agent PI3K inhibitors in PDAC cells is only evident when
oncogenic KRAS is absent. Although the MAPK pathway
dependence on PI3K has been demonstrated previously31, 32, 52,
53, we reveal a novel induced dependency on PI3K activity due to
loss of oncogenic KRAS expression and provide evidence that this
rewiring occurs at the level of wild-type RAS.
Despite the fact that PI3K has typically been considered a RAS
effector, a growing body of evidence suggests that PI3K can act
upstream to stimulate RAS–MAPK signaling in various contexts.
Our data demonstrates that RAS mutant cancer cells in which
mutant RAS is ablated or RASWT PDAC cells (e.g., BxPC3) show
PI3K-dependent MAPK activation. Recent work from Rosen and
colleagues revealed that PI3K inhibition in breast cancer cells
harboring oncogenic PI3K mutations induces a transient decrease
in RAS–MAPK signaling, which could be blunted by expression
of exogenous mutant RAS32. Interestingly, this response is not
limited to cancer cells, as PI3K inhibition in human embryonic
kidney cells (Supplementary Fig. 10c) and hematopoietic
progenitor cells54, 55 also reduced MAPK signaling. Though the
precise nature of how PI3K stimulates RAS–MAPK activation in
KRAS deﬁcient PDAC cells remains unclear, we speculate that
this could be due to alterations in GAP activity, recruitment via
Gab1/Shp256, or phospholipid signaling54. Nonetheless, we show
that PI3K transitions to an upstream targetable regulator of not
only the canonical AKT pathway, but also the RAS–MAPK
pathway when oncogenic KRAS is lost. Additionally,
we demonstrate that biochemical evidence of transient MAPK
inhibition is a better predictive biomarker for PI3K inhibitor
sensitivity than PI3K/AKT pathway hyperactivation (Supple-
mentary Figs. 7 and 10b, c).
We further took advantage of KRAS intact and deﬁcient cell
lines to identify novel KRAS-regulated pathways in PDAC. These
include the upregulation of genes associated with ribosomal
biogenesis and protein translation and the downregulation of
genes associated with interferon response and the metastatic
cascade. Moreover, we developed a 16-gene signature, suppressed
by KRAS, with independent prognostic value in PDAC validated
in two different patient cohorts (TCGA and ICGC). Finally, we
demonstrated that our KRAS knockout signatures are enriched in
PDAC CTCs relative to primary tumors. Given these data and
evidence that CTCs display expression of genes downregulated by
oncogenic KRAS in multiple contexts, we propose that decreased
KRAS activity may promote gene expression changes that drive
metastasis. Moreover, we hypothesize that the poor prognoses
observed with the quasi-mesenchymal, basal, and squamous
subtypes is a consequence of decreased KRAS activity leading to
greater metastatic potential in these human tumors. Consistent
with this hypothesis, epigenetic rather than genetic mechanisms
appear to mediate metastasis in human PDAC tumors57, 58.
While further work is needed in primary human specimens to
conﬁrm the relationship between KRAS activity and metastasis,
our work highlights KRAS-relevant gene signatures as indepen-
dent prognostic factors in PDAC.
In summary, we have shown that KRAS, the hallmark mutated
gene in PDAC, is dispensable in a subset of PDAC cells.
We identiﬁed novel functions of KRAS in altering gene
expression balancing proliferation and metastasis. Finally, our
data demonstrate that canonical and non-canonical PI3K
pathway activation may bypass the requirement for KRAS in
PDAC and that simultaneous inhibition of KRAS and PI3K may
be a viable combinatorial therapeutic strategy for this disease.
Methods
Cell lines and culture conditions. Cell lines used in this study are described in
Supplementary Table 2. Established human PDAC cell lines were obtained from
the Broad Institute Cancer Cell Line Encyclopedia, sourced from DSMZ-Germany,
American Type Culture Collection (ATCC), and RIKEN, and identity authenti-
cated by DNA ﬁngerprinting by the Broad Institute. Primary human PDAC cell
lines (PACO9 and PACO19) were obtained as previously described59. Brieﬂy, cell
lines were derived from pancreatic cancer tissue specimens obtained from patients
admitted to the Department of General, Visceral, and Transplantation Surgery at
the University of Heidelberg under a protocol approved by the ethical committee of
the University of Heidelberg (301/2001) and conducted in accordance with the
Helsinki Declaration. Informed consent was obtained from all patients. Mouse
PDAC cell lines were derived from primary pancreatic tumors from LSL-KrasG12D;
p53ﬂox/ﬂox; Pdx1-CreER mice treated with tamoxifen (Sigma) to induce oncogenic
KrasG12D activation and biallelic p53 inactivation in the pancreas60 or from the
LSL-KrasG12D; p53R172H/WT; Pdx1-Cre (KPC) mouse model61. All cell lines tested
negative for mycoplasma by PCR testing.
Cells were maintained in DMEM (Corning Cellgro) supplemented with 10%
fetal bovine serum (FBS) (Hyclone) and penicillin/streptomycin or RPMI-1640
(Corning Cellgro) supplemented with 10% FBS, L-glutamine, and penicillin/
streptomycin. PACO cell lines were grown in serum-free medium as previously
described59. For inducible-shRNA experiments, doxycycline (DOX, Sigma) was
used at 1 μg mL−1 in culture media and replaced every 2–3 days. Cell viability was
analyzed after 5 days of DOX treatment using the CellTiter-Glo (CTG)
luminescence assay (Promega), which measures cellular ATP levels as a surrogate
for cell number and growth. Luminescence was read on a Tecan M2000 Inﬁnite Pro
plate reader. Cells were imaged with a Nikon Eclipse TE2000-U light microscope
and SPOT RT3 camera.
Cloning of sgRNA and overexpression constructs. Lentiviral constructs for
CRISPR/Cas-mediated genome editing from the dual-vector lentiviral
GeCKOv2 system, lentiCas9-Blast and lentiGuide-Puro62 (Supplementary Fig. 1a),
were provided by Dr Feng Zhang. sgRNAs targeting human and mouse KRAS
exons were designed (Supplementary Table 1) and ligated into the BsmBI site
with compatible annealed oligos. lentiGuide-Hygro (Supplementary Fig. 1a) was
generated following sgRNA ligation by subcloning a hygromycin resistance gene
PCR ampliﬁed from MSCV-Luciferase-pPGK-Hygro (Addgene #18782) into BsiWI
and MluI sites. pLKO-Tet-On constructs (Supplementary Fig. 1c) targeting KRAS
(shKRAS.407) and LACZ (shLACZ.1650) and pLKO constructs targeting YAP1
(shYAP1.1573 and shYAP1.1928) and LACZ (shLACZ.1650) were provided by Dr
William Hahn (Supplementary Table 1). mmKras.366 sgRNA targeting mouse Kras
was cloned into a lentiviral vector for DOX-inducible sgRNA expression provided
by Dr Marco Herold63. To generate lentiviral constructs for overexpression, we
ﬁrst produced LV-pSV40-mCherry-pPGK-FlpO, LV-pSV40-Puro-pPGK-eGFP, and
LV-pSV40-Blast-pPGK-eGFP by assembling four parts with overlapping DNA ends
into a 5.7 kb lentiviral backbone using Gibson assembly (New England Biolabs) as
previously described64. PCR ampliﬁed cDNAs (Supplementary Table 5) were
subcloned into AfeI and AscI sites to replace FlpO and eGFP and veriﬁed by
sequencing and restriction digest. Alternatively, cDNAs were subcloned into the
EcoRI and BamHI sites of pBABE-zeo (Addgene #1766) or pBABE-puro (Addgene
#1764) retroviral vectors. The translation reporter construct MSCV-mCherry-IRES-
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GFP was generated by subcloning PCR ampliﬁed mCherry into the XhoI and
EcoRI sites of MSCV-IRES-GFP (Addgene #9044). High-ﬁdelity restriction
enzymes (New England Biolabs) were used for restriction digests when available.
Cloning methods and primer sequences not detailed in this manuscript are
available upon request.
Lentiviral and retroviral production and transduction. For lentiviral infections,
lentiviral backbone, packaging vector (delta8.2 or psPAX2), and envelope (VSV-G)
were transfected into 293T cells with TransIT-LT1 (Mirus Bio). Supernatant was
collected at 48 and 72 h and applied to target cells with 8 μg mL−1 polybrene (EMD
Millipore) for transduction. Transduced cells were treated with 10 μg mL−1 blas-
ticidin S (Life Technologies), 2–4 μg mL−1 puromycin (Life Technologies), 400 μg
mL−1 hygromycin B (Roche), or 400 μg mL−1 zeocin (Life Technologies) for
3–7 days, as appropriate, for antibiotic selection. Alternatively, Cas9-Blast-
expressing cells were transfected with lentiGuide-Puro harboring sgKRAS to induce
KRAS knockout (8988T T1 and T2 cells) using the Amaxa Nucleofector Kit for
Mammalian Epithelial Cells (Lonza). To generate single cell clones from sgKRAS-
transduced cells, we sorted one cell per well into 96-well plates using a FACSAria II
(Becton Dickinson) or MoFlo (Beckman Coulter) FACS sorter. Alternatively,
PACO clones were manually picked from culture plates following low-density
plating. Intact clones were derived from lentiGuide-Puro- or lentiGuide-Hygro-
transduced cells without inserted guide sequence (empty vector) except for 8988T
E1, which was derived from hsKRAS.22V-transduced cells but exhibited loss of
Cas9 protein expression, no mutagenesis, and KRAS intact cell properties. sgKRAS
vectors used to generate knockout clones are listed in Supplementary Table 3. For
overexpression constructs harboring mCherry, ﬂuorescent cells were sorted using a
FACSAria II sorter. For retroviral infections, the retroviral backbone and pCL-Eco
(for mouse cells) or pUVMC and VSV-G (for human cells) were transfected into
293T cells. For the translational reporter experiments, ﬂuorescence was assessed
using an LSR II FACS analyzer (Becton Dickinson) and data were analyzed using
FlowJo software.
In vitro growth assays. Anchorage-independent growth was assessed by plating
10,000 cells in 0.4% low melting temperature agarose (Seaplaque) in complete
media on top of a 0.8% preformed agarose layer. Cells were grown for 9–14 days
and colonies were stained with 0.5% crystal violet and destained with water.
Microscopic images of the colonies were taken pre- and post-crystal violet staining.
For growth curves, 250–1000 cells were plated on day 0 and grown for 5 days in
culture. Four–ﬁve replicates for each cell line per day were assessed for cell viability
by CTG assay. Cell viability results were normalized to luminescence at day 0.
Three-dimensional culture was established by plating 250–500 cells from a single
cell suspension onto a growth factor-reduced matrigel (Corning) layer, allowing
cell migration into matrigel for 4–6 h. Cells were grown in complete media for
7–10 days prior to analysis. Three technical replicates were performed for each
clone. Apoptosis was measured using the Guava Nexin Reagent per the manu-
facturer’s instructions and analyzed on a Guava ﬂow cytometry system (Millipore).
Immunoblotting. Cells were lysed with ice-cold RIPA buffer (Pierce), supple-
mented with 0.5 μM EDTA and Halt protease and phosphatase inhibitors (Thermo
Scientiﬁc), rotated at 4 °C for 15–30 min to mix, and centrifuged at maximum
speed for 15 min to collect whole cell lysates. Protein concentration was measured
with the BCA protein assay (Pierce). An aliquot of 20–30 μg of total protein per
sample was loaded into 4–12% Bis–Tris gradient gels (Life Technologies) and
separated by SDS-PAGE. Proteins were transferred to nitrocellulose (for LI-COR)
or PVDF (for ECL) membranes. The following antibodies were used for immu-
noblotting: mouse anti-HSP90 (BD #610418, 1:10,000), rabbit anti-beta-tubulin
(CST 2128, 1:1000), mouse anti-KRAS (SCBT sc-30, 1:200), mouse anti-NRAS
(SCBT sc-31, 1:200), mouse anti-HRAS (SCBT sc-29, 1:200), rabbit anti-pERK1/2
(T202/Y204) (CST 4370, 1:1000), mouse anti-ERK1/2 (CST 9107, 1:1000), rabbit
anti-pAKT(S473) (CST 4060, 1:2000), rabbit anti-pAKT(T308) (CST 2965, 1:1000),
mouse anti-AKT (CST 2966, 1:2000), rabbit anti-pPRAS40(T246) (CST 2997,
1:1000), rabbit anti-PTEN (CST 9559, 1:1000), rabbit anti-INPP4B (Abcam
ab81269, 1:1000), rabbit anti-pS6(S235/236) (CST 4858, 1:2000), mouse anti-S6
(CST 2317, 1:1000), rabbit anti-4EBP1(S65) (CST 9451, 1:1000), rabbit anti-
pCRAF(S338) (CST 9427, 1:1000), rabbit anti-pMEK1/2(S217/221) (CST 9154,
1:1000), mouse anti-MEK1/2 (CST 4694, 1:1000), rabbit-anti-c-MYC (Abcam
ab32072, 1:1000), rabbit anti-c-MYC (CST 5605, 1:1000), and rabbit anti-YAP1
(CST 4912, 1:1000). HSP90 and beta-Tubulin were used as loading controls. RAS-
GTP assays were performed using an Active RAS Pull-Down and Detection Kit
(Thermo Scientiﬁc 16117) per the manufacturer’s instructions using in vitro
GTPγS (non-hydrolysable) and GDP pull-down controls and the provided pan-
RAS antibody (1:200). Mouse RTK arrays (R&D Systems) were assayed per the
manufacturer’s instructions. Primary antibodies were detected with ﬂuorescent
DyLight-conjugated (CST) or HRP-conjugated (BioRad) secondary antibodies for
ﬂuorescent (LI-COR) or chemiluminescent detection (Amersham), respectively.
Approximate locations of protein size markers (in kDa) are shown in individual
blots. Quantiﬁcation of protein levels from western blots was performed using
Image Studio Lite (LI-COR).
Genomic DNA isolation and sequencing. Genomic DNA from cell lines was
collected using QuickExtract DNA extraction solution (Epicentre) or a QiaAMP
DNA Mini Kit (Qiagen). PCR products for sequencing were ampliﬁed using a
Herculase II Fusion DNA polymerase kit (Agilent) and primers described in
Supplementary Table 6. PCR products from cell lines were subject to Sanger
sequencing (Quintara Biosciences). For subclones with multiple KRAS mutant
alleles, PCR products were cloned into a TOPO vector (Life Technologies) and at
least 10–20 bacterial colonies were sequenced per cell line. The most probable off-
target genes for sgRNAs were identiﬁed using CRISPR Design (http://crispr.mit.
edu) and no gene had fewer than three exonic mismatches. All sequences and
chromatograms were analyzed using MacVector software.
Genomic DNA was isolated from ground ﬂash frozen tumor tissue using a High
Pure PCR Template Preparation Kit (Roche). Mouse Kras exon 3 was PCR
ampliﬁed using Herculase II Fusion DNA polymerase. Sequencing libraries were
prepared from 50 ng of PCR product using the Nextera DNA Sample Preparation
Kit (Illumina) and sequenced with Illumina MiSeq. Sequencing reads (150 bp
paired-end) were trimmed to 120 bp after reviewing base quality proﬁles, in order
to drop lower quality 3′ ends. Traces of Nextera adapters were clipped using the
FASTX toolkit (Hannon Lab, CSHL) and pairs with each read greater than 15 bp in
length were retained. Additionally, read pairs where either read had 50% or more
bases below a base quality threshold of Q30 (Sanger) were dropped from
subsequent analyses. The reference sequence of the target locus was supplemented
with 10 bp genomic ﬂanks and was indexed using an enhanced sufﬁx array. Read
ends were anchored in the reference sequence using 10 bp terminal segments for a
sufﬁx array index lookup to search for exact matches. A sliding window of unit step
size and a maximal soft-clip limit of 10 bp was used to search for possible anchors
at either end of each read. For each read, optimal Smith-Waterman dynamic
programming alignment was performed between the reduced state space of the
read sequence and the corresponding reference sequence spanning the maximally
distanced anchor locations. Scoring parameters were selected to allow for sensitive
detection of short and long insertions and deletions while allowing for up to four
mismatches, and the highest scoring alignment was selected. Read pairs with both
reads aligned in the proper orientation were processed to summarize the number of
wild-type reads and the location and size of each insertion and deletion event.
Overlapping reads within pairs were both required to support the event if they
overlapped across the event location. Additionally, mutation events and wild-type
reads were summarized within the extents of the sgRNA sequence and PAM site by
considering read alignments that had a minimum of 20 bp overlap with this
region. Mutation calls were translated to genomic coordinates and subsequently
annotated using Annovar (http://annovar.openbioinformatics.org). The alignment
and post-processing code was implemented in C++ along with library functions
from SeqAn (https://www.seqan.de/) and SSW65 and utility functions in Perl and
in the R statistical programming language (www.R-project.org). Mutation calls
were subjected to manual review using the Integrated Genomics Viewer (IGV;
http://software.broadinstitute.org/software/igv/).
Quantitative PCR for copy number analysis. Quantitative PCR of the KRAS
locus and control regions (LINE1 for human, chromosome 5 10054507–10054621
region for mouse) was performed as previously described66, 67 in triplicate using
SYBR green reagents (Life Technologies) with primers listed in Supplementary
Table 7. Genomic DNA from 293T and murine ES cells were used as control cells
to determine 2N copy number for human and mouse samples, respectively. Cp
values were measured by a LightCycler 480 Real-Time PCR System (Roche).
KRAS DNA relative to control region (KRASamp) was calculated for samples
and control cell lines using the following formula: 2(KRAS Cp-Control region Cp).
KRAS copy number was determined using the following formulation: 2 x KRASamp
(sample)/KRASamp (control cell line).
High-throughput drug screening. High-throughput screening was performed as
previously described68. To determine the optimal plating density during assay
development, 8988T E3, E6, H9, and H36 cells were plated at either 500, 1000, or
1500 cells per well into 384-well opaque, white assay plates (Corning), 50 μL per
well, and incubated overnight at 37 °C/5% CO2. The next day, cells were treated
with MG-132 (Enzo Bioscience) starting at a high concentration of 40 μM, in a 14-
pt, twofold dilution series, 16 replicates/concentration, for 72 h. 0.1% DMSO
(solvent for all compounds) was used as a negative control. Sensitivity was assayed
using CTG. Luminescence was measured using a M1000 Inﬁnite Pro plate reader
(Tecan). The Z′ factor at each concentration point was calculated and compared
between each cellular density to determine the largest dynamic detection window
for subsequent screening. Estimated Z′ factors were calculated using the following
formula: 1 − (3 × (σp + σn)/(μp − μn)) where σ (standard deviation) and μ (mean)
were determined from the positive (p) and negative (n) controls. For the screen,
cells were plated at a density optimized during assay development as above. A
modiﬁed version of the Selleck Cambridge Cancer Compound Library (http://
www.selleckchem.com/screening/cambridge-cancer-compound-library.html) con-
taining 384 structurally diverse, medicinally active, and cell permeable cancer-
relevant compounds was used for screening. Compounds were plated in 384-well
format in 5-pt, 10-fold concentration ranges, starting at 10 mM. 50 nL of com-
pounds were pin-transferred (V&P Scientiﬁc pin tool mounted onto a Tecan
Freedom Evo 150 MCA96 head) into duplicate assay plates and incubated for 72 h.
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The DMSO content was 0.1% within each well. Thirty-two wells of DMSO vehicle
control and 32 wells of positive control MG-132 were included on each plate. After
3 days of incubation, 10 μL of CTG was added to each well, incubated for 10 min,
and luminescence output was read as a surrogate for cell viability. Z′ factors were
>0.5 for all plates in the screen. Percent viability (PV) compared to DMSO control
was calculated for each compound well and plotted against log10(Dose) (M). Area
under the curve (AUC) was calculated using the trapezoidal rule: ((PV1 + PV2)/
2) × (dose1 − dose2). AUCs were averaged for intact (AUCi) and knockout
(AUCKO) cells across replicates. Compounds were considered hits if (1) AUCi or
AUCKO were <4; (2) ΔAUC (AUCi –AUCKO) was >0.5 or <−0.5; and (3) AUCi
and AUCKO were signiﬁcantly different (p< 0.05, Student’s t test).
Drug treatments. GDC-0941, BAY80-6946, AZD6244, MK2206, AZD8055,
BYL719, TGX220, Idelalisib, BGJ-398, and Crenolanib were purchased from Sell-
eck Chemical. Verteporﬁn was purchased from Sigma. All compounds were diluted
to 10–50 mM stock concentration in DMSO except for BAY80-6946, which was
diluted to 5 mM in DMSO with 10 mM triﬂuoroacetic acid (TFA). To generate
dose-response curves, cells (500–1000 for A13 clones, 2000–4000 for PANC-1
clones and primary hPDAC clones, and 1000–2000 for 8988T, KP-4, and MM1402
clones) were plated in 96-well white plates (Perkin Elmer) in 100 μL of media and
incubated overnight. Hundred microliter of drug at 2× ﬁnal concentration was
added to each well for 3–6 replicates for each cell line and dose. Cell viability was
determined at 72 h using CTG. For ligand treatments, cells were treated with
recombinant EGF, FGF1, or PDGF-BB (R&D Systems) when initially plated.
Percent viability was calculated for each dosed well compared to solvent controls
(DMSO or DMSO with TFA at 0.1–0.2%) and plotted against log10(Dose) (M). For
dose-response curves, each replicate for each cell line and dose was plotted along
with curve ﬁt regression for three-component inhibitor response (Prism). For long-
term drug treatments, cells were plated at low-density in six-well plates in triplicate,
treated with drugs for 10–14 days (media was refreshed with drug every 2 days),
and stained with 0.5% crystal violet when control cells became conﬂuent.
Animal studies. All animal studies were approved by the MIT Institutional
Animal Care and Use Committee. A13 mouse clones were transplanted to form
tumors in nude mice (Taconic) via subcutaneous injections. A total of 5 × 105 cells
suspended in 100 μL of cold PBS were injected per tumor to determine tumor-
forming capacity. For 8988T and PANC-1 clones, 2 × 106 cells suspended in 100 μL
of cold 3:1 PBS:growth factor-reduced matrigel (Corning) were injected per tumor.
For drug treatment of A13 tumors in vivo, a higher number of knockout cells
(2 × 106) was injected to synchronize tumor formation between intact and
knockout clones, as 5 × 105 cells of K1 and K2 give rise to subcutaneous tumors but
at signiﬁcantly slower rates than E1 and E2. Tumor formation was monitored over
time by direct observation, caliper measurement, and IVIS spectrum optical ima-
ging (Xenogen Corporation). When subcutaneous tumors grew to 0.5 cm in dia-
meter (approximate bioluminescent radiance of 1 × 1010 photons s−1 cm−2 per sr),
mice were randomly dosed (based on ear tag number assigned at time of tumor
transplant) with 150 mg kg−1 of GDC-0941 (LC Laboratories) or vehicle alone
(10% DMSO and 5% Tween-20 in nuclease-free water) daily for 14 days by oral
gavage. We estimated that to observe a 50% reduction in tumor growth at 2 weeks
after initiation of treatment (mean normalized volume± s.d. of 12± 4) with alpha
of 0.05 and power of 0.8, we would need at least seven tumors per group.
For transplant of A13 cells harboring DOX-inducible mmKras.366, 5 × 105 cells
suspended in 100 μL of cold PBS were injected per tumor subcutaneously. Clone 1
was injected to the left ﬂank and clone 2 to the right ﬂank of each
immunocompromised mouse. DOX feed (Harlan-Teklad) was administered after
all the tumors were 0.5 cm in diameter as monitored by caliper measurements.
After 4 days of DOX feed, 150 mg kg−1 of GDC-0941 or vehicle alone was dosed
daily for 14 days by oral gavage. Caliper measurements and bioluminescence
imaging by IVIS was done in 3–4 day intervals by injecting 100 μl of 30 mgml−1
luciferin per mouse and imaging 10 min post injection. The level of
bioluminescence in radiance was analyzed by Living Image software (Perkin
Elmer). Tumor volume was calculated from caliper measurements using the
modiﬁed ellipsoid formula: (length) × (width)2/2. Investigators were not blinded
to treatment groups during protocol. Bliss independence for additive effect of
DOX-induced KRAS knockout and GDC-0941 treatment was calculated for
each measured time point using the following formulas: Fractional response to
GDC-0941 (FGDC)= (1−(TVGDC/TVVeh)), Fractional response to DOX-induced
KRAS knockout (FDOX)= (1−(TVDOX/TVVeh)), additive fractional response to
GDC-0941 and DOX (FGDC+DOX) = FGDC + FDOX − (FGDC × FDOX). Bliss line
corresponds to tumor volume (TV) with predictive additive effect of
treatments and determined with the following equation at each time point:
TVVeh(1 − FGDC +DOX).
RNA isolation and sequencing analysis. RNA was isolated from PDAC cells
using TRIzol (Life Technologies). cDNA libraries were prepared using an Illumina
TruSeq sample preparation kit with indexed adapter sequences and polyA selec-
tion. Sequencing was performed on an Illumina HiSeq 2000 instrument to obtain
single-end 50-nt reads. All reads that passed quality metrics were mapped to the
UCSC mm9 mouse or hg19 human genome build (http://genome.ucsc.edu/) using
RSEM (v1.2.12) (http://deweylab.github.io/RSEM/). For pairwise differential
expression analyses, data normalization (MedianNorm) and differential analyses
between experimental conditions were performed using EBSeq v1.4.0 (http://
bioconductor.org/packages/release/bioc/html/EBSeq.html). All RNA-Seq analyses
were conducted in R. Unsupervised clustering was performed using a Pearson
correlation-based pairwise distance measure. Heat maps were generated using the
Heatplus package in R.
High-resolution signature analyses between clones within each cell line were
performed using a blind source separation methodology based on ICA69. RSEM
generated estimated expression counts were upper quartile normalized to a count
of 1000. The R implementation of the core JADE algorithm (Joint Approximate
Diagonalization of Eigenmatrices)70 was used along with custom R utilities.
Signatures were visualized using the sample-to-signature correspondence
schematic afforded by Hinton plots, where colors represent relative directionality of
gene expression (red relatively upregulated, blue relatively downregulated within
each signature) and the size of each rectangle quantiﬁes the strength of a signature
(column) in a given sample (row). Each signature is two-sided, allowing for
identiﬁcation of upregulated and downregulated genes for each signature within
each sample. Biologically relevant and statistically signiﬁcant signatures were
identiﬁed using a Mann–Whitney U-test. Signature correlation scores (z-scores) for
each gene in the statistically signiﬁcant signatures are included as supplementary
tables. Heat maps were plotted with the top and bottom 2% genes in each
signature. Additionally, genes with standardized signature correlation scores z> 3
(alternatively z< −3) were used as gene sets to score TCGA (https://tcga-data.nci.
nih.gov/tcga/) Pancreatic adenocarcinoma (PAAD) tumors using ssGSEA. Tumors
were stratiﬁed based on standardized signature scores (z-scores) derived using
ssGSEA and associated patients within matching top and bottom percentile buckets
were compared for a statistically signiﬁcant difference in survival times.
Signiﬁcance of overlap between tumor buckets scored using 8988T, A13, combined
knockout, quasi-mesenchymal21, basal46, and squamous45 subtype signatures was
assessed using the hypergeometric test. Survival analyses were conducted using the
survival package in R.
In order to derive a combined knockout signature, the top and bottom 2% genes
in the human signature were analyzed in the mouse expression data set and ICA
analysis revealed a WT/KO signature. The up and down gene sets were determined
using a standardized signature correlation score of z> 0.5 (alternatively, z < −0.5).
These were used in survival analyses similar to those described above for TCGA
and also for ICGC Pancreatic Cancer Australia (PACA-AU) tumors (https://icgc.
org/icgc/cgp/68/304/798).
Publicly available microarray data sets were used to generate KRAS-ON and
KRAS-OFF signatures from a mouse model of DOX-regulated KRAS transgene
expression22, 39, 40. Array CEL ﬁles were retrieved from GEO (GSE32277,
GSE53169, and GSE58307) and processed using Affymetrix Power Tools v. 1.15.0
(rma-sketch). Probes were collapsed (max. value) to yield per gene expression
estimates. Genes with upper quartile log2 expression value less than 5 across all
samples were dropped from further analysis. The resulting data sets were used for
signature analysis with ICA.
Publicly available RNA-Seq data sets were used to generate the CTC
signature44. Read counts for the sample set (number of raw reads mapped per
gene) were downloaded from GEO for record GSE51372. Entries with duplicate
symbols or missing gene names were dropped from further consideration. Samples
with less than 5 million total mapped reads were dropped from the data set in order
to eliminate expression noise from low coverage. Only samples identiﬁed as tumor
or classical CTC were retained for downstream analyses. Read counts for the
remaining samples were normalized using quartile normalization with the upper
quartile set to 1000. In the resulting expression data set, genes with an upper
quartile of expression count less than 1000 across all samples were tagged as lowly
expressed genes and dropped. Normalized expression values were log2 transformed
and used as input for signature analysis using ICA.
GSEA were carried out using the pre-ranked mode using log2 fold-change
values (for pairwise analyses) or standardized signature correlation scores (for ICA
signatures) with default settings38. Network representations of GSEA results were
generated using EnrichmentMap (http://www.baderlab.org/Software/
EnrichmentMap) for Cytoscape v3.3.0 (http://www.cytoscape.org) with p value and
FDR cutoffs as described in ﬁgure legends. Each circle represents a gene set with
circle size corresponding to gene set size and intensity corresponding to
enrichment signiﬁcance. Red is upregulated and blue is downregulated. Each line
corresponds to minimum 50% mutual overlap with line thickness corresponding to
degree of overlap. Cellular processes for gene set clusters were manually curated.
Candidate point mutations in RNA-Seq data sets were called using a pipeline
based on the GATK Toolkit (https://software.broadinstitute.org/gatk/).
Transcriptomic reads were mapped (to mm9, hg19) using the Tophat (v2.0.4)
spliced aligner and subjected to local realignment and score recalibration using the
GATK Toolkit. Mutations were called in KO samples (individual and pooled)
against WT samples (individual and pooled) with a minimum base quality
threshold of 30. Genomic annotations were performed using ANNOVAR (http://
www.openbioinformatics.org/annovar/).
Statistical analyses. P values for comparisons of two groups were determined by
two-tailed Student’s t test (for normally distributed data) or Mann–Whitney U-test
(for non-parametric data) as noted in the ﬁgure legends. All replicates were
included in these analyses. The log-rank test was used for Kaplan–Meier survival
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analyses. The Cox regression model (in univariate and multivariable settings) was
used to estimate hazard ratios in survival analyses. A p value of < 0.05 was used to
denote statistical signiﬁcance. All error bars denote standard error of mean (s.e.m.)
or standard deviation (s.d.) as noted in the ﬁgure legends.
Code availability. Computer code for RNA-Seq independent component analyses
is available upon request. Other software tools for RNA-Seq analyses, website
source, and version numbers are listed above.
Data availability. The RNA and DNA sequencing data sets that support the
ﬁndings of this study have been deposited in the Gene Expression Omnibus (GEO)
and the NCBI Sequencing Read Archive (SRA) under accession GSE71876.
Previously published data sets used in this study are available in GEO under
accession GSE32277, GSE53169, GSE58307, and GSE51372. The authors declare
that all other data are available within the article and its supplementary infor-
mation ﬁles or available from the corresponding author upon request.
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